Feng et al. found that sesquiterpene compound 113, the reversible cholinesterase inhibitor, is a promising new drug candidate for the treatment of Alzheimer’s Disease and a preclinical trial is already under way [54]. Here, BCHE is linked to Alzheimer disease.